CClinicalTrials.gg
Status unknownNCT04610177Updated Jan 12, 2021

Prospective Multicenter Study of Artificial Intelligence-assisted Quality Evaluation System for Colonoscopy

An observational study in Quality Evaluation System for Colonoscopy, sponsored by Renmin Hospital of Wuhan University. Status unknown at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Renmin Hospital of Wuhan University · Observational

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,813
Ages
50 Years to 80 Years
Sex
All
01

Study summary

The quality control index based on artificial intelligence is put forward to monitor the quality of enteroscopy. And we will verify the correlation between the detection rate of adenomas and the percentage of endoscopic overspeed mirrors, the number of times of no-return/successful return, the real-time Bowel preparation provided by EndoAngel. What's more, it is expected that the standard range of quality control index for standard operation of colonoscopy can be proposed according to the detection rate of adenomas.

Read the detailed description

Colonoscopy is a key technique for detection and diagnosis of Lower Gastrointestinal Diseases. High-quality endoscopy leads to better outcomes, However, the skill level of different endoscopists is quite different. The rate of missed diagnosis of colorectal ADENOMAS was 22%, the rate of missed diagnosis ranged from 7.4% to 52.5% . A series of studies showed that 12.1% of patients did not have cancer during colonoscopy but were diagnosed with colorectal cancer (post-colonoscopy Colorectal Cancer, PCCRC) within 5 years, of which 71%-86% could be attributed to the negligence of the endoscopist 6, seven. Therefore, it is very important to improve the quality of routine endoscopic examination while expanding the endoscopic technique.

The quality control index of colonoscope can reflect the operation level of endoscopy doctors, and it is a very important tool to ensure the quality of colonoscope. The examination and feedback of the quality control data of the endoscopist can effectively improve the detection rate of lesions and guarantee the high level of endoscopic quality. It is the key to guarantee the quality of enteroscopy to put forward the quality control index which can reflect the quality of endoscopist operation. Barclay proposed in 2006 that there was a significant correlation between colonoscopy withdrawal time and the rate of Adenomas in patients, and their findings were published in the The New England Journal of Medicine, with an impact factor of 70.67. Then, there were 367 papers on the study of the speed of enteroscopy withdrawal. Aslinia made a retrospective analysis of the correlation between the incidence of blindness reached by enteroscopy and the prognosis of patients, and proposed the incidence of blindness reached as a quality control index for enteroscopy. Other quality control indicators, such as bowel cleanliness and polyp detection rate, have been published in international well-known journals and included in the guidelines to regulate the quality of daily work of endoscopic physicians, which has great clinical significance.

However, despite the above-mentioned quality control indicators, the existing endoscopic quality control indicators are seriously inadequate. According to a multicenter clinical study, current quality control indicators only reflect about 40% of the difference in lesion detection levels between endoscopic physicians. The existence of this phenomenon indicated that more quality control indexes are needed to fully reflect the quality of endoscopic procedures. As a quality control index reflecting intestinal preparation, intestinal cleanliness is a fatal defect with strong subjectivity and poor consistency among observers, therefore, the existing colonoscopy need more comprehensive, objective quality control indicators to reflect the level of endoscopic doctors, so as to ensure the quality of colonoscopy.

In the past decade, artificial intelligence (AI) has made remarkable progress in the medical field. Andre Esteva used a deep neural network (DNN) to classify skin cancer with expert-level accuracy. In the field of digestive endoscopy, the project team in the early is made a huge breakthrough. In 2018, the artificial intelligence gastroscopy blind spot monitoring model developed by the project team significantly reduced the endoscopy blind spot in randomized controlled clinical trials, the findings were published in the journal Gut with an impact factor of 17.94. In 2019, the team's artificial intelligence model for evaluating gut cleanliness, published in the journal gastrogastrotestinal endoscopy with an impact factor of 7.23, showed better picture accuracy than that of the endoscopist in the human computer competition. In the same year, the project developed a model for colonoscopy speed monitoring based on Hasche perception algorithm and a model for colonoscopy slide mirror monitoring based on image classification, and conducted randomized controlled clinical trials, the model significantly improved The ability of colonoscopists to detect lesions, The study was published in The Lancet Gastroenterology 18 with an impact factor of 12.87.

Based on the above-mentioned rich foundation of early work, as well as the current great demand in the field of quality control of enteroscopy, we intend to validate the artificial intelligence-based enteroscopy exit velocity, bowel cleanliness, and enteroscopy slide model developed by the project team through a multi-center clinical study, to evaluate the feasibility and accuracy of doctor's operation quality as a quality control index.

02

Conditions studied

  • Quality Evaluation System for Colonoscopy
03

In context

Lead sponsor

Renmin Hospital of Wuhan University is the lead sponsor of 83 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A total of 5813 patients were enrolled in this study. It included male and female subjects aged 50-80 years who were required to undergo colonoscopies, voluntarily provide endoscopic imaging and sign an informed consent form.

Inclusion criteria

  1. Male or female aged 50-80(inclusive) ;
  2. Ability to read, understand and sign an informed consent form;
  3. The researchers believed that the subjects were able to understand the flow of the clinical study and were willing and able to complete all the procedures and follow-up interviews to accompany the study.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study

  1. Drug or alcohol abuse or psychological disorders in the last 5 years;
  2. Pregnant or lactating women;
  3. Patients with known Polyp Syndrome;
  4. Patients with known Inflammatory Bowel Disease;
  5. Patients with known Intestinal stricture or mass tumor;
  6. Patients with known colonic obstruction or perforation;
  7. Patients with a previous history of colorectal surgery;
  8. Patients with a previous history of Anaphylaxis to antispasmodic agents;
  9. Blood coagulation disorders or oral anticoagulants and other reasons can not be biopsy and polypectomy;
  10. High-risk diseases or other special conditions considered unsuitable for participants in clinical trials.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,813 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Percentage of enteroscopy exit velocity overdrive

    Percentage of enteroscopy exit velocity overdrive

    Time frame: 2020.12.2

  2. The adenoma detection rate(ADR)

    ADR was calcilated by dividing the tatal number of patients being detected adenomas by the number of colinoscopies.

    Time frame: 2020.12.2

Secondary outcomes

  1. The advanced adenoma detection rate

    The advanced adenoma detection rate was calcilated by dividing the tatal number of patients being detected advanced adenomas by the number of colinoscopies.

    Time frame: 2020.12.2

  2. The polyp detection rate(PDR)

    PDR was calcilated by dividing the tatal number of patients being detected polyps by the number of colinoscopies.

    Time frame: 2020.12.2

  3. The mean number of adenomas per patient(MAP)

    MAP was calculated by dividing the total number of adenomas by the number of colonoscopies.

    Time frame: 2020.12.2

  4. PDR of different size

    It was calculated by dividing the number of patients with polyps that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Time frame: 2020.12.2

  5. MNP of different size

    It was calculated by dividing the number of polyps that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Time frame: 2020.12.2

  6. ADR of different size

    It was calculated by dividing the number of patients with adenomas that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Time frame: 2020.12.2

  7. MAP of different size

    It was calculated by dividing the number of adenomas that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Time frame: 2020.12.2

  8. ADR of different location

    It was calculated by dividing the number of patients with adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, ileocecal region ect. by the total number patients undergoing colonoscopy.

    Time frame: 2020.12.2

  9. MAP of different location

    It was calculated by dividing the number of adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, ileocecal region ect. by the total number patients undergoing colonoscopy.

    Time frame: 2020.12.2

  10. Cecal intubation rate

    It was calculated by dividing the number of colonoscopies that get to the ileocecal region by the total number of colonoscopies.

    Time frame: 2020.12.2

  11. Cleanliness assessment of different intestinal segment in the artificial intelligence system

    The artificial intelligence evaluates the Boston Bowel Preparation score of the ascending colon, transverse colon,and descending colon in real-time, and calculates the proportion of 1Score.

    Time frame: 2020.12.2

07

Study locations

1 of 1 sites recruiting
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430000, China
    • Honggang Yu, Doctor · Contact · yuhonggang@whu.edu.cn · 13871281899
    • Liwen Yao, Doctor · Contact · 15827416837
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual de-identified participant data that underlie the results reported in this article and study protocol will be shared for investigators whose proposed use of the data has been approved by an independent review committee. Data can only be used to achieve aims in the approved proposal. Data disclosure begins 9 months and ends 36 months after article publication. To gain access, data requesters will need to sign a data access agreement. Proposals should be directed to the corresponding author.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04610177
Lead sponsor
Renmin Hospital of Wuhan University
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Jun 2, 2020
Primary completion
Dec 2, 2021 (estimated)
Completion
Dec 16, 2021 (estimated)
Last update
Jan 12, 2021

Study contacts

Honggang Yu, Doctoc
Contact
yuhonggang@whu.edu.cn
13871281899
Liwen Yao, Doctor
Contact
15827416837
Honggang Yu, Doctor
principal investigator · Renmin Hospital of Wuhan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion